TG Therapeutics KGV 2024

Što radi TG Therapeutics?

TG Therapeutics Inc is a biopharmaceutical company based in New York City, USA. The company was founded in 2012 and focuses on the development and commercialization of innovative therapy options for various types of cancer and autoimmune diseases. TG Therapeutics was founded as a result of a collaboration between Michael S. Weiss, an experienced investment banker and biotechnology manager, and Laurence N. Charous, an oncologist and clinical researcher. The company has roots in two predecessor companies: Manhattan Pharmaceuticals and LFB Biotechnologies. Both had failed, and TG rose from their remains. TG Therapeutics' business model is to develop a new therapy option by combining drugs of different drug classes that target the needs of patients with specific cancer conditions. The dual blockade approach, which simultaneously inhibits various signaling pathways that sustain tumor cells, is particularly promising. TG Therapeutics operates a diversified portfolio strategy and has several drug candidates in different stages of development for numerous cancer conditions, including diffuse large B-cell lymphoma, chronic lymphocytic leukemia, and multiple myeloma, as well as autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus. TG Therapeutics' main products for cancer treatments currently are umapalisib and umbralisib, both of which are PI3K delta inhibitors and are being developed for the treatment of non-Hodgkin lymphomas and chronic lymphocytic leukemia. TG-1101 (Ublituximab) is a CD20-targeted antibody therapy used in lymphomas and autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus. TG Therapeutics' research and development efforts are driven by an experienced team of oncologists and scientists, including CEO Michael S. Weiss. The company maintains close relationships with academic institutions and research facilities. TG Therapeutics holds a broad patent portfolio covering technologies and compounds that can be used in cancer and autoimmune disease treatment. In 2020, TG Therapeutics' revenue reached approximately $109 million, compared to $14 million in the previous year. This increase in revenue was due to the sales of umbralisib. However, the company has not yet received FDA approval for any of its drugs in the US. TG Therapeutics expects that the future success of the company will be based on the clinical activity of its pipeline, market acceptance of its products, and successful completion of studies and regulatory approvals. As of December 31, 2020, TG Therapeutics had 248 employees. The company's leading body, the board of directors, consists of an experienced team of executives and advisors, including Chairman and CEO Michael S. Weiss, CFO Sean A. Power, CMO Adam D. Feuerstein, and COO Scott T. Smith. TG Therapeutics has had a tumultuous past, but the company can now look forward to a promising pipeline and a very strong financial position. The research and development of this biopharmaceutical company are promising, and it remains to be seen which of the research products will actually break through and be introduced to the market. TG Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.